


FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 00-873-I (500.011)	Serial No. 10/715,285
 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: Thompson et al.	
		Filing Date: November 17, 2003	Group: 1635

U.S. PATENT APPLICATION DOCUMENTS


Examiner Initial		Document Number	Filing Date	Name	Class	Subclass	Publication Date if Appropriate
JZ	*	09/103,636	06/23/98	Thompson et al.			
	*	09/886,316	05/25/01	Thompson et al.			
	*	60/082,404	04/20/98	Thompson et al.			
	*	60/101,074	09/21/98	Hartmann, et al.			

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
JZ	*	4,987,071	01/22/91	Cech et al.			
	*	5,013,830	05/07/91	Ohtsuka et al.			
	*	5,144,019	09/01/92	Rossi et al.			
	*	5,264,423	11/23/93	Cohen et al.			
	*	5,272,065	12/21/93	Inouye et al.			
	*	5,276,019	01/04/94	Cohen et al.			
	*	5,286,717	02/15/94	Cohen et al.			
	*	5,334,711	08/02/94	Sproat et al.			

EXAMINER JZ	DATE CONSIDERED 4/12/06
--------------------	--------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 00-873-I (500.011)	Serial No. 10/715,285
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: Thompson et al.	
(Use several sheets if necessary)		Filing Date: November 17, 2003	Group: 1635 

83	*	5,491,133	02/13/96	Walder et al.			
	*	5,496,698	03/05/96	Draper et al.			
	*	5,525,468	06/11/96	McSwiggen			
	*	5,576,208	11/19/96	Monia et al.			
	*	5,587,362	12/24/96	Chu et al.			
	*	5,623,065	04/22/97	Cook et al.			
	*	5,624,803	04/29/97	Noonberg et al.			
	*	5,625,047	04/29/97	Been et al.			
	*	5,627,053	05/06/97	Usman et al.			
	*	5,631,359	05/20/97	Chowrira et al.			
	*	5,633,133	05/27/97	Long et al.			
	*	5,652,094	07/29/97	Usman et al.			
	*	5,652,355	07/29/97	Metelev et al.			
	*	5,652,356	07/29/97	Agrawal			
	*	5,678,731	10/21/97	Okamura et al.			
	*	5,716,824	02/10/98	Beigelman et al.			
	*	5,849,902	12/15/98	Arrow et al.			
	*	5,919,619	07/06/99	Tullis			

EXAMINER	DATE CONSIDERED
	4/12/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 00-873-I (500.011)	Serial No. 10/715,285
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: Thompson et al.	
		Filing Date: November 17, 2003	Group: 1635

83	*	5,989,912	11/23/99	Arrow et al.			
	*	5,998,203	12/07/99	Matulic-Adamic et al.			
	*	6,001,311	12/12/00	Brennan			
	*	6,001,653	12/04/99	Crooke et al.			
	*	6,127,173	10/03/00	Eckstein et al.			
	*	6,159,714	12/14/99	Usman et al.			
	*	6,365,730	02/02/02	Jennings et al.			
	*	6,420,546	07/16/02	Seliger et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
83	*	0 360 257 A2	03/28/90	EPO (Hampel et al.)				
	*	89/02439	03/23/89	WO (Arnold et al.)				
	*	91/03162	03/21/91	WO (Rossi et al.)				
	*	92/07065	04/30/92	WO (Eckstein et al.)				
	*	93/15187	08/05/93	WO (Usman et al.)				
	*	93/23569	11/25/93	WO (Draper et al.)				

EXAMINER	DATE CONSIDERED 4-12-06
-----------------	--------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 00-873-I (500.011)	Serial No. 10/715,285
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: Thompson et al.	
		Filing Date: November 17, 2003	Group: 1635

83	*	94/02595	02/03/94	WO (Sullivan et al.)				
	1.	95/06731	03/09/95	WO (Usman et al.)				
	*	95/11910	05/04/95	WO (Dudycz)				
	*	96/10390	04/11/96	WO (Ansell et al.)				
	*	96/10391	04/11/96	WO (Choi et al.)				
	*	96/10392	04/11/96	WO (Holland et al.)				
	*	96/17086	06/06/96	WO (Joyce et al.)				
	*	96/18736	06/20/96	WO (Beigelman et al.)				
	*	96/19577	06/27/96	WO (Collins)				
	*	97/26270	07/24/97	WO (Wincott et al.)				
	*	98/13526	04/02/98	WO (Woolf)				
	*	98/58058	12/23/98	WO (Ludwig et al.)				
	*	99/04819	02/04/99	WO (Klimuk et al.)				
	*	99/05094	07/22/98	WO (Beigelman et al.)				
	*	99/16871	04/08/99	WO (Eckstein et al.)				
	*	99/54459	10/28/99	WO (Thompson et al.)				
	*	99/55857	04/28/99	WO (Beigelman et al.)				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

EXAMINER	DATE CONSIDERED
83	4/12/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 00-873-I (500.011)	Serial No. 10/715,285
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: Thompson et al.	
(Use several sheets if necessary)		Filing Date: November 17, 2003	Group: 1635

8-3	*	Abramovitz et al., "Catalytic Role of 2'-Hydroxyl Groups Within a Group II Intron Active Site," <u>Science</u> 271:1410-1413 (1996)
		Agrawal et al., "Site-specific excision from RNA by RNase H and mixed-phosphate-backbone oligodeoxynucleotides," <u>Proc. Nat. Acad. Sci. USA</u> 87:1401-1405 (1990)
	2.	Agrawal et al., "Antisense therapeutics: is it as simple as complementary base recognition?" <u>Molecular Medicine Today</u> , 6:72-81 (2000)
	*	Akhtar and Juliano, "Cellular uptake and intracellular fate of antisense oligonucleotides," <u>Trends in Cell Biology</u> 2:139-144 (1992)
	*	Aldrian-Herrada et al., "A peptide nucleic acid (PNA) is more rapidly internalized in cultured neurons when coupled to a <i>retro-inverso</i> delivery peptide. The antisense activity depresses the target mRNA and protein in magnocellular oxytocin neurons," <u>Nucleic Acids Research</u> 26:4910-4916 (1998)
	*	Altmann et al., "Second generation of antisense oligonucleotides: From nuclease resistance to biological efficacy in animals," <u>Chimia</u> 50:168-176 (1996)
	*	Ashley, "Modeling, Synthesis, and Hybridization Properties of (L)-Ribonucleic Acid," <u>J. Am. Chem. Soc.</u> 114:9731-9736 (1992)
	*	Banerjee and Turner, "The Time Dependence of Chemical Modification Reveals Slow Steps in the Folding of a Group I Ribozyme," <u>Biochemistry</u> 34:6504-6512 (1995)
	*	Bartel and Szostak, "Isolation of New Ribozymes From a Large Pool of Random Sequences," <u>Science</u> 261:1411-1418 (1993)
	*	Beaucage et al., "The functionalization of oligonucleotides via phosphoramidite derivatives," <u>Tetrahedron</u> 49:1925-1963 (1993)
	*	Beaudry et al., "Directed Evolution of an RNA Enzyme," <u>Science</u> 257:635-641 (1992)
	*	Beigelman et al., "Chemical Modification of Hammerhead Ribozymes," <u>J. Biol. Chem.</u> 270:25702-25708 (1995)
	*	Bellon et al., "Amino-Linked Ribozymes: Post-Synthetic Conjugation of Half-Ribozymes," <u>Nucleosides & Nucleotides</u> 16:951-954 (1997)
	*	Bellon et al., "Post-synthetically Ligated Ribozymes: An Alternative Approach to Iterative Solid-Phase Synthesis," <u>Bioconjugate Chem.</u> 8:204-212 (1997)
	3.	Bennett et al., "Pharmacology of Antisense Therapeutic Agents," <u>Methods in Molecular Medicine</u> , 13-46 (1996)
	*	Berzal-Herranz et al., "Essential nucleotide sequences and secondary structure elements of the hairpin ribozyme," <u>EBMO J.</u> 12:2567-2574 (1993)

EXAMINER	DATE CONSIDERED
8-3	4/12/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 00-873-I (500.011)	Serial No. 10/715,285
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: Thompson et al.	
		Filing Date:	Group:
		November 17, 2003	1635

83	*	Berzal-Herranz et al., "In vitro selection of active hairpin ribozymes by sequential RNA-catalyzed cleavage and ligation reactions," <i>Genes & Development</i> 6:129-134 (1992)
	*	Bevilacqua et al., "A Mechanistic Framework for the Second Step of Splicing Catalyzed by the <i>Tetrahymena</i> Ribozyme," <i>Biochemistry</i> 35:648-658 (1996)
	*	Boado et al., "Drug Delivery of Antisense Molecules to the Brain for Treatment of Alzheimer's Disease and Cerebral AIDS," <i>Journal of Pharmaceutical Sciences</i> 87:1308-1315 (1998)
	*	Boado, "Antisense drug delivery through the blood-brain barrier," <i>Advanced Drug Delivery Reviews</i> 15:73-107 (1995)
	*	Borras et al., "Estradiol-induced Down-regulation of Estrogen Receptor. Effect of Various Modulators of Protein Synthesis and Expression," <i>J. Steroid Biochem. Molec. Biol.</i> 48:325-336 (1994)
	*	Borras et al., "Estrogenic and Antiestrogenic Regulation of the Half-life of Covalently Labeled Estrogen Receptor in MCF-7 Breast Cancer Cells," <i>J. Steroid Biochem. Molec. Biol.</i> 57:203-213 (1996)
	4.	Branch, "A good antisense molecule is hard to find," <i>TIBS</i> 23:45-50 (1998)
	*	Breaker and Joyce, "Inventing and improving ribozyme function: rational design versus iterative selection methods," <i>TIBTECH</i> 12:268-275 (1994)
	*	Breaker et al., "A DNA enzyme with Mg ²⁺ -dependent RNA phosphoesterase activity," <i>Chemistry & Biology</i> 2(10):655-660 (1995)
	*	Breaker, "Are engineered proteins getting competition from RNA?" <i>Current Opinion in Biotechnology</i> 7:442-448 (1996)
	*	Breaker, "Catalytic DNA: in training and seeking employment," <i>Nature Biotechnology</i> 17:422-423 (1999)
	*	Brennan et al., "Two-Dimensional Parallel Array Technology as a New Approach to Automated Combinatorial Solid-Phase Organic Synthesis," <i>Biotechnology and Bioengineering (Combinatorial Chemistry)</i> 61:33-45 (1998)
	*	Burgin et al., "Chemically Modified Hammerhead Ribozymes with Improved Catalytic Rates," <i>Biochemistry</i> 35:14090-14097 (1996) (volume no mistakenly listed as 6)
	*	Burke et al., "Structural Analysis and Modifications of the Hairpin Ribozyme," <i>Nucleic Acids and Molecular Biology</i> , edited by Eckstein and Lilley, Springer-Verlag Berlin Heidelberg, 10:129-143 (1996)
	*	Burlina et al., "Chemical Engineering of Rnase Resistant and Catalytically Active Hammerhead Ribozymes," <i>Bioorganic & Medicinal Chemistry</i> 5:1999-2010 (1997)
	*	Cao and Matteucci, "Preparation, Characterization and Binding Properties of an Oligodeoxynucleotide Containing the 3'-Ribothioformacetal Phosphate Analog," <i>Bioorganic & Medicinal Chemistry Letters</i>

EXAMINER	83	DATE CONSIDERED	4/12/06
----------	----	-----------------	---------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 00-873-I (500.011)	Serial No. 10/715,285
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: Thompson et al.	
(Use several sheets if necessary)		Filing Date: November 17, 2003	Group: 1635

J3		4:807-810 (1994) Caruthers et al., "Chemical Synthesis of Deoxyoligonucleotides and Deoxyoligonucleotide Analogs," <u>Methods in Enzymology</u> 211:3-19 (1992)
		Cech et al., "Representation of the secondary and tertiary structure of group I introns," <u>structural biology</u> 1:273-280 (1994)
		Cech, "Ribozymes and Their Medical Implications," <u>JAMA</u> 260:3030-3034 (1988)
		Chartrand et al., "An oligodeoxyribonucleotide that supports catalytic activity in the hammerhead ribozyme domain," <u>Nucleic Acids Research</u> 23(20):4092-4096 (1995)
		Chen et al., "Multitarget-Ribozyme Directed to Cleave at up to Nine Highly Conserved HIV-1 env RNA Regions Inhibits HIV-1 Replication-Potential Effectiveness Against Most Presently Sequenced HIV-1 Isolates," <u>Nucleic Acids Research</u> 20:4581-4589 (1992)
		Chowrira et al., "In Vitro and in Vivo Comparison of Hammerhead, Hairpin, and Hepatitis Delta Virus Self-Processing Ribozyme Cassettes," <u>J. Biol. Chem.</u> 269:25856-25864 (1994)
		Chowrira et al., "Novel guanosine requirement for catalysis by the hairpin ribozyme," <u>Nature</u> 354:320-322 (1991)
		Christoffersen and Marr, "Ribozymes as Human Therapeutic Agents," <u>J. Med. Chem.</u> 38:2023-2037 (1995) (also referred to as Christofferson and Marr)
		Christoffersen, "Translating genomics information into therapeutics: A Key Role for Oligonucleotides," <u>Nature Biotechnology</u> 15:483-484 (1997) (Christofferson)
		Christofferson et al., "Application of computational technologies to ribozyme biotechnology products," <u>Journal of Molecular Structure (Theochem)</u> 311:273-284 (1994) (Christofferson)
		Cload and Schepartz, "Polyether Tethered Oligonucleotide Probes," <u>J. Am. Chem. Soc.</u> 113:6324-6326 (1991)
	5.	Cook et al., "Ch. 9 - Medicinal Chemistry Strategies for Antisense Research," <u>Antisense Research and Applications</u> , CRC Press, Inc., pp. 140-181 (1993)
		Cook et al., "The Use of Antisense Oligonucleotides to Establish Autocrine Angiotensin Growth Effects in Human Neuroblastoma and Mesangial Cells," <u>Antisense Research and Development</u> 2:199-210 (1992)
		Cosstick et al., "Synthesis and properties of dithymidine phosphate analogues containing 3'-thiothymidine," <u>Nucleic Acids. Research</u> 18:829-835 (1990)
		Couture and Stinchcomb, "Anti-gene therapy: the use of ribozymes to inhibit gene function," <u>Trends In Genetics</u> 12:510-515 (1996)

EXAMINER	J3	DATE CONSIDERED	4/12/06
----------	----	-----------------	---------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 00-873-I (500.011)	Serial No. 10/715,285
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: Thompson et al.	
		Filing Date: November 17, 2003	Group: 1635

83	*	Crooke et al., "Kinetic characteristics of <i>Escherichia coli</i> RNase H1: Cleavage of various antisense oligonucleotide-RNA duplexes," <i>Biochem. J.</i> 312:599-608 (1995)
	6.	Crooke et al., "Progress in the development and patenting of antisense drug discovery technology," <i>Exp. Opin. Ther. Patents</i> , 6, 855 (1996)
	*	Crooke, "Progress in Antisense Therapeutics," <i>Medicinal Research Reviews</i> 16:319-344 (1996)
	*	Crooke, "Advances in Understanding the Pharmacological Properties of Antisense Oligonucleotides," <i>Advances in Pharmacology</i> 40:1-49 (1997)
	*	Crooke, "Antisense Therapeutics," <i>Biotechnology and Genetic Engineering Reviews</i> 15:121-157 (1998)
	*	Crooke, "Progress in Antisense Technology: The End of the Beginning," <i>Methods in Enzymology</i> 313:3-45 (1999)
	*	Daniels et al., "Two Competing Pathways for Self-splicing by Group II Introns: A Quantitative Analysis of <i>in Vitro</i> Reaction Rates and Products," <i>J. Mol. Biol.</i> 256:31-49 (1996)
	*	deFazio et al., "Antisense Estrogen Receptor RNA Expression Increases Epidermal Growth Factor Receptor Gene Expression in Breast Cancer Cells," <i>Cell Growth & Differentiation</i> 8:903-911 (1997)
	*	Delihias et al., "Natural antisense RNA/target RNA interactions: Possible models for antisense oligonucleotide drug design," <i>Nature Biotechnology</i> 15:751-753 (1997)
	*	Dreyfus, "Restriction Ribozymes?" <i>Einstein Quarterly Journal of Biology and Medicine</i> 6:92-93 (1988)
	*	Dropulic et al., "Functional Characterization of a U5 Ribozyme: Intracellular Suppression of Human Immunodeficiency Virus Type I Expression," <i>Journal of Virology</i> 66:1432-1441 (1992)
	*	Durand et al., "Circular Dichroism Studies of an Oligodeoxyribonucleotide Containing a Hairpin Loop Made of a Hexaethylene Glycol Chain: Conformation and Stability," <i>Nucleic Acids Research</i> 18:6353-6359 (1990)
	*	Duval-Valentin, "Specific inhibition of transcription by triple helix-forming oligonucleotides," <i>Proc. Natl. Acad. Sci. USA</i> 89:504-508 (1992)
	*	Earnshaw et al., "Modified Oligoribonucleotides as Site-Specific Probes of RNA Structure and Function," <i>Biopolymers</i> 48:39-55 (1998)
	*	Egholm et al., "PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules," <i>Nature</i> 365:566-568 (1993)
	7.	Elkins and Rossi, "Ch. 2 - Cellular Delivery of Ribozymes," in <i>Delivery Strategies for Antisense Oligonucleotide Therapeutics</i> , edited by Akhtar, CRC Press, pp. 17-220 (1995)
	*	Elroy-Stein and Moss, "Cytoplasmic Expression System Based on Constitutive Synthesis of

EXAMINER 	DATE CONSIDERED 4/14/06
--	-------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 00-873-I (500.011)	Serial No. 10/715,285
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: Thompson et al.	
(Use several sheets if necessary)		Filing Date: November 17, 2003	Group: 1635

93		Bacteriophage T7 RNA Polymerase in Mammalian Cells," <u>Proc. Natl. Acad. Sci. USA</u> 87:6743-6747 (1990)
	*	Emerich et al., "Biocompatibility of Poly (DL-Lactide-co-Glycolide) Microspheres Implanted Into the Brain," <u>Cell Transplantation</u> 8:47-58 (1999)
	*	Ferentz and Verdine, "Disulfied Cross-Linked Oligonucleotides," <u>J. Am. Chem. Soc.</u> 113:4000-4002 (1991)
	8.	Flanagan et al., "Cellular penetration and antisense activity by a phenoxazine-substituted heptanucleotide," <u>Nature Biotechnology</u> , Vol. 17, No. 1, pages 48-52 (Jan. 1999)
	*	Forster and Altman, "External Guide Sequences for an RNA Enzyme," <u>Science</u> 249:783-786 (1990)
	*	Fox, "Targeting DNA with Triplexes," <u>Current Medicinal Chemistry</u> 7:17-37 (2000)
	*	Freier et al., "Improved free-energy parameters for predictions of RNA duplex stability," <u>Proc. Natl. Acad. Sci. USA</u> 83:9373-9377 (1986)
	*	Gao and Huang, "Cytoplasmic Expression of a Reporter Gene by Co-Delivery of T7 RNA Polymerase and T7 Promoter Sequence with Cationic Liposomes," <u>Nucleic Acids Research</u> 21:2867-2872 (1993)
	*	Gold, "Axonal Regeneration of Sensory Nerves is Delayed by Continuous Intrathecal Infusion of Nerve Growth Factor," <u>Neuroscience</u> 76:1153-1158 (1997)
	*	Good et al., "Expression of small, therapeutic RNAs in human nuclei," <u>Gene Therapy</u> 4:45-54 (1997)
	*	Grasby et al., "Purine Functional Groups in Essential Residues of the Hairpin Ribozyme Required for Catalytic Cleavage of RNA," <u>Biochemistry</u> 34:4068-4076 (1995)
	*	Green et al., "Human oestrogen receptor cDNA: sequence, expression and homology to <i>v-erb-A</i> ," <u>Nature</u> 320:134-139 (1986)
	9.	Green et al., "Antisense Oligonucleotides: An Evolving Technology for the Modulations of Gene Expression in Human Disease," <u>J. Am. Coll. Surg.</u> , 93-105 (2000)
	*	Griffin et al., "Group II intron ribozymes that cleave DNA and RNA linkages with similar efficiency, and lack contacts with substrate 2'-hydroxyl groups," <u>Chemistry & Biology</u> 2:761-770 (1995)
	*	Groothuis et al., "The entry of antiviral and antiretroviral drugs into the central nervous system," <u>J. NeuroVirol</u> 3:387-400 (1997)
	*	Guo and Collins, "Efficient <i>trans</i> -cleavage of a stem-loop RNA substrate by a ribozyme derived from <i>Neurospora</i> VS RNA," <u>EMBO J.</u> 14:368-376 (1995)
	*	Hammann et al., "Length Variation of Helix III in a Hammerhead Ribozyme and Its Influence on Cleavage Activity," <u>Antisense & Nucleic Acid Drug Development</u> 9:25-31 (1999)
	*	Hampel et al., "'Hairpin' Catalytic RNA Model: Evidence for Helices and Sequence Requirement for

EXAMINER	83	DATE CONSIDERED	4/12/06
----------	----	-----------------	---------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 00-873-I (500.011)	Serial No. 10/715,285
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: Thompson et al.	
(Use several sheets if necessary)		Filing Date: November 17, 2003	Group: 1635

93	Substrate RNA," <u>Nucleic Acids Research</u> 18:299-304 (1990)
*	Harris et al., "Identification of phosphates involved in catalysis by the ribozyme RNase P RNA," <u>RNA</u> 1:210-218 (1995)
*	Haseloff and Gerlach, "Simple RNA Enzymes with New and Highly Specific Endoribonuclease Activities," <u>Nature</u> 334:585-591 (1988)
*	Hegg et al., "Kinetics and Thermodynamics of Intermolecular Catalysis by Hairpin Ribozymes," <u>Biochemistry</u> 34:15813-15828 (1995)
*	Henningfeld et al., "Alteration of DNA Primary Structure by DNA Topoisomerase I. Isolation of the Covalent Topoisomerase I-DNA Binary Complex in Enzymatically Competent Form," <u>J. Am. Chem. Soc.</u> 118:11701-11714 (1996)
*	Herschlag and Cech, "Catalysis of RNA Cleavage by the <i>Tetrahymena thermophila</i> Ribozyme 1. Kinetic Description of the Reaction of an RNA Substrate Complementary to the Active Site," <u>Biochemistry</u> 29:10159-10171 (1990)
*	Herschlag and Cech, "Catalysis of RNA Cleavage by the <i>Tetrahymena thermophila</i> Ribozyme. 2. Kinetic Description of the Reaction of an RNA Substrate That Forms a Mismatch at the Active Site," <u>Biochemistry</u> 29:10172-10180 (1990)
*	Hertel et al., "A Kinetic Thermodynamic Framework for the Hammerhead Ribozyme Reaction," <u>Biochemistry</u> 33:3374-3385 (1994)
*	Hertel et al., "Numbering System for the Hammerhead," <u>Nucleic Acids Research</u> 20:3252 (1992)
*	Higson et al., "Synthesis and Structure of S-Nucleosidyl S-Aryl Disulfides and their Reaction with Phosphites," <u>Tetrahedron</u> 52:1027-1034 (1996)
10.	Ho et al., "Antisense Oligonucleotides for Target Validation in the CNS," <u>Current Opinion in Molecular Therapeutics</u> 1:336-343 (1999)
*	Hostomsky et al., "Ch. 11 - Ribonucleases H," in <u>Nucleases</u> , edited by Linn et al., Cold Spring Harbor Laboratory Press, NY, pp. 341-376 (1993)
*	Inoue et al., "Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and RNase H," <u>FEBS Letters</u> 215:327-330 (1987)
*	Inoue et al., "Synthesis and hybridization studies on two complementary nona(2'-O-methyl) ribonucleotides," <u>Nucleic Acids Research</u> 15:6131-6149 (1987)
*	Ishiwata et al., "Physical-Chemistry Characteristics and Biodistribution of Poly(ethylene glycol)-Coated Liposomes Using Poly(oxyethylene) Cholesteryl Ether," <u>Chem. Pharm. Bull.</u> 43:1005-1011 (1995) (mistakenly referred to as Ishiwataet)

EXAMINER	DATE CONSIDERED
	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 00-873-I (500.011)	Serial No. 10/715,285
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: Thompson et al.	
(Use several sheets if necessary)		Filing Date: November 17, 2003	Group:

83	11.	Ishizaka et al., "Isolation of Active Ribozymes from an RNA Pool of Random Sequences Using an Anchored Substrate RNA," <u>Biochemical and Biophysical Research Communication</u> 214(2):403-409 (1995)
	*	Izant and Weintraub, "Constitutive and Conditional Suppression of Exogenous and Endogeneous Genes by Anti-Sense RNA," <u>Science</u> 229:345-352 (1985)
	*	Jaeger et al., "Improved Predictions of Secondary Structures for RNA," <u>Proc. Natl. Acad. Sci. USA</u> 86:7706-7710 (1989)
	*	Jankowsky et al., "Peptide nucleic acid (PNA) is capable of enhancing hammerhead ribozyme activity with long but not with short RNA substrates," <u>Nucleic Acids Research</u> 25:2690-2693 (1997)
	*	Jaschke et al., "Automated Incorporation of Polyethylene Glycol into Synthetic Oligonucleotides," <u>Tetrahedron Letters</u> 34:301-304 (1993)
	*	Jeffries and Symons, "A Catalytic 13-mer Ribozyme," <u>Nucleic Acids Research</u> 17:1371-1377 (1989) (also referred to as Jefferies)
	12.	Jen et al., "Suppression of gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies," <u>Stem Cells</u> , 18:307-319 (2000)
	*	Jiang et al., "Growth Regulation of Estrogen Receptor-Negative Breast Cancer Cells Transfected with Complementary DNAs for Estrogen Receptor," <u>J. Natl. Cancer Inst.</u> 84:580-591 (1992)
	*	Joffe-Riant and Tillement, "Drug transfer across the blood-brain barrier and improvement of brain delivery," <u>Fundam. Clin. Pharmacol.</u> 13:16-26 (1999)
	*	Jordan et al., "Endocrine Pharmacology of Antiestrogens as Antitumor Agents," <u>Endocrine Reviews</u> 11:78-610 (1990)
	*	Joseph et al., "Substrate selection rules for the hairpin ribozyme determined by in vitro selection, mutation, and analysis of mismatched substrates," <u>Genes & Development</u> 7:130-138 (1993)
	*	Joseph et al., "Amplification, mutation and selection of catalytic RNA," <u>Gene</u> 82:83-87 (1989)
	*	Joseph, "Directed Molecular Evolution," <u>Scientific American</u> 267:90-97 (1992)
	*	Kaplan et al., "2'-O-Methylthiomethyl Modifications In Hammerhead Ribozymes," <u>Nucleosides & Nucleotides</u> 16(7-9):955-958 (1997)
	*	Karlsky et al., "Highly Efficient Synthesis of 2'-O-Amino Nucleosides And Their Incorporation in Hammerhead Ribozymes," <u>Tetrahedron Letters</u> 39:1131-1134 (1998)
	*	Karlsky-Sabet et al., "Reversal of the Malignant Phenotype by an Anti-ras Ribozyme," <u>Antisense Research & Development</u> 2:3-15 (1992)
	*	Kim and Cech, "Three-dimensional model of the active site of the self-splicing rRNA precursor of

EXAMINER	83	DATE CONSIDERED	4/12/06
----------	----	-----------------	---------

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 00-873-I (500.011)	Serial No. 10/715,285
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: Thompson et al.	
(Use several sheets if necessary)		Filing Date: November 17, 2003	Group: 1635

83		<i>Tetrahymena</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 84:8788-8792 (1987)
	*	Kim et al., "Inhibition of Transcription of the Human <i>c-myc</i> Protooncogene by Intermolecular Triplex," <i>Biochemistry</i> 37:2299-2304 (1998)
	*	Klubmann et al., "Mirror-image RNA that binds D-adenosine," <i>Nature Biotechnology</i> 14:1112-1115 (1996)
	*	Knitt et al., "pH Dependencies of the <i>Tetrahymena</i> Ribozyme Reveal an Unconventional Origin of an Apparent pK _a ," <i>Biochemistry</i> 35:1560-1570 (1996)
	13.	Koga et al., "Alternating α,β -Oligothymidylates with Alternating (3'→3')- and (5'→5') – Internucleotidic Phosphodiester Linkages as Models for Antisense Oligodeoxyribonucleotides," <i>The Journal of Organic Chemistry</i> , 56:3757-2759 (1991)
	*	Kore, et al., "Sequence specificity of the hammerhead ribozyme revisited; the NIH rule", <i>Nucleic Acids Research</i> , 26(18):4116-4120 (1998).
	*	Kumar and Ellington, "Artificial evolution and natural ribozymes," <i>FASEB J.</i> 9:1183-1195 (1995)
	*	Lasic and Needham "The 'Stealth' Liposome: A Prototypical Biomaterial," <i>Chemical Reviews</i> 95:2601-2627 (1995)
	*	Lasic and Papahadjopoulos, "Liposomes Revisited," <i>Science</i> 267:1275-1276 (1995)
	*	Letmann et al., "Solid-phase synthesis of oligoribonucleotides using 9-fluorenylmethoxycarbonyl (Fmoc) for 5'-hydroxyl protection," <i>Nucleic Acids Research</i> 17:2379-2390 (1989)
	*	L'Huillier et al., "Cytoplasmic Delivery of Ribozymes Leads to Efficient Reduction in α -Lactalbumin mRNA Levels in C1271 Mouse," <i>EMBO J.</i> 11:4411-4418 (1992)
	*	Muller, "Application of the Michaelis-Arbusov Reaction to the Synthesis of Internucleoside 3'-S-Phosphorothiolate Linkages," <i>J. Chem. Soc. Perkin Trans. I</i> 15:2123-2129 (1994)
	*	Muller, "Synthesis of a Dinucleoside 3'-S-Phosphorothiolate Containing 2'-Deoxy-3'-Thioadenosine," <i>Chem. Commun.</i> 48:2729-2738 (1992)
	*	Li et al., "Thermodynamic and Activation Parameters for Binding of a Pyrene-Labeled Substrate by the <i>Tetrahymena</i> Ribozyme: Docking is Not Diffusion-Controlled and is Driven by a Favorable Entropy Change," <i>Biochemistry</i> 34:14394-14399 (1995)
	*	Muller et al., "Stable High-Level Gene Expression in Mammalian Cells by T7 Phage RNA Polymerase," <i>Gene</i> 127:47-66 (1993)
	*	Muller et al., "Summary: the modified nucleosides of RNA," <i>Nucleic Acids Research</i> 22(12):2183-2194 (1994)
	*	Muller et al., "Automatic Identification of Group I Intron Cores in Genomic DNA Sequences," <i>J. Mol. Biol.</i> 267:1275-1276 (1995)

EXAMINER	83	DATE CONSIDERED	8/12/06
----------	----	-----------------	---------

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.


FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 00-873-I (500.011)	Serial No. 10/715,285
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: Thompson et al.	
		Filing Date: November 17, 2003	Group: 1635

93		Biol. 235:1206-1217 (1994)
	*	Lisiewicz et al., "Inhibition of Human Immunodeficiency Virus Type 1 Replication by Regulated Expression of a Polymeric Tat Activation Response RNA Decoy as a Strategy for Gene Therapy in AIDS," <u>Proc. Natl. Acad. Sci. U.S.A.</u> 90:8000-8004 (1993)
	*	Liu et al., "3'-Thiouridylyl-(3'→5')-uridine," <u>Tetrahedron Letters</u> 37:925-928 (1996)
	*	Liu et al., "Cationic Liposome-mediated Intravenous Gene Delivery," <u>J. Biol. Chem.</u> 270(42):24864-24870 (1995)
	*	Long and Uhlenbeck, "Kinetic characterization of intramolecular and intermolecular hammerhead PNAs with stem II deletions," <u>Proc. Natl. Acad. Sci. USA</u> 91:6977-6981 (1994)
	*	Ma et al., "Design and Synthesis of RNA Miniduplexes via a Synthetic Linker Approach," <u>Biochemistry</u> 32:1751-1758 (1993)
	*	Ma et al., "Design and Synthesis of RNA Miniduplexes via a Synthetic Linker Approach. 2. Generation of Covalently Closed, Double-Stranded Cyclic HIV-1 TAR RNA Analogs with High Tat-Binding Affinity," <u>Nucleic Acids Research</u> 21:2585-2589 (1993)
	14.	Ma et al., "Synthetic oligonucleotides as therapeutics: the coming of age," <u>Biotechnology Annual Review</u> , 5:155-196 (2000)
	*	Majumdar and Adamic et al., "Synthesis and Incorporation of 2'-Amino Acid Conjugated Nucleotides Into Ribozymes," <u>Biorganic & Medicinal Chemistry Letters</u> 5:2721-2724 (1995)
	*	Majumdar and Adamic et al., "Synthesis and Incorporation of 5'-Amino- and 5'-Mercapto-5'-Deoxy-2'-O-Methyl Nucleosides Into Hammerhead Ribozymes," <u>Nucleosides & Nucleotides</u> 16:1933-1950 (1997)
	*	Mazumdar et al., "Enduring Consequences of Neonatal Treatment with Antisense Deoxyribonucleotides to Estrogen Receptor Messenger Ribonucleic Acid on Sexual Differentiation of the Brain," <u>Endocrinology</u> 133:433-439 (1993)
	*	Murdock et al., "Deoxyoligonucleotides with Inverted Polarity: Synthesis and Use in Triple-Helix Formation," <u>Nucleosides & Nucleotides</u> 10:287-290 (1991)
	*	Muller and Lindquist, "Inhibition of heat shock protein synthesis by heat-inducible antisense RNA," <u>Proc. Natl. Acad. Sci. USA</u> 83:399-403 (1986)

EXAMINER	93	DATE CONSIDERED	4/12/06
----------	----	-----------------	---------

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 00-873-I (500.011)	Serial No. 10/715,285
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: Thompson et al.	
		Filing Date: November 17, 2003	Group: 1635

	*	Michel et al., "Structure and Activities of Group II Introns," <u>Annu. Rev. Biochem.</u> 64:435-461 (1995)
	*	Michels and Pyle, "Conversion of a Group II Intron into a New Multiple-Turnover Ribozyme that Selectively Cleaves Oligonucleotides: Elucidation of Reaction Mechanism and Structure/Function Relationships," <u>Biochemistry</u> 34:2965-2977 (1995)
	*	Mitra et al., "A mammalian 2-5A system functions as an antiviral pathway in transgenic plants," <u>Proc. Natl. Acad. Sci. USA</u> 93:6780-6785 (1996)
	*	Monia et al., "Evaluation of 2'-Modified Oligonucleotides Containing 2'-Deoxy Gaps as Antisense Inhibitors of Gene Expression," <u>J. Biol. Chem.</u> 268:14514-14522 (1993)
	*	Moore and Sharp, "Site-Specific Modification of Pre-mRNA: The 2'-Hydroxyl Groups at the Splice Sites," <u>Science</u> 256:992-996 (1992)
	*	Mukhopadhyay et al., "Antisense Regulation of Oncogenes in Human Cancer," <u>Critical Reviews in Oncogenesis</u> 7:151-190 (1996)
	*	Nakamaye and Eckstein, "AUA-Cleaving Hammerhead Ribozymes: Attempted Selection for Improved Cleavage," <u>Biochemistry</u> 33:1271-1277 (1994)
	*	Nathans and Smith, "Restriction Endonucleases in the Analysis and Restructuring of DNA Molecules," <u>Ann. Rev. Biochem.</u> 44:273-293 (1975)
	*	Norberg et al., "In vivo generation of highly abundant sequence-specific oligonucleotides for antisense and index gene regulation," <u>Nucleic Acids Research</u> 22(14):2830-2836 (1994)
	*	Ohnaka et al., "Activities of HIV-RNA Targeted Ribozymes Transcribed From a 'Shot-Gun' Type Ribozyme Trimming Plasmid," <u>Nucleic Acids Symp. Ser.</u> 27:15-16 (1992)
	*	Oliver et al., "Inhibition of Human Immunodeficiency Virus Type 1 Expression by a Hairpin Ribozyme," <u>Proc. Natl. Acad. Sci. USA</u> 89:10802-10806 (1992)
	*	Okabe et al., "Real-time analysis of liposomal trafficking in tumor-bearing mice by use of positron emission tomography," <u>Biochimica et Biophysica Acta</u> 1238:86-90 (1995)
	*	Okamoto et al., "DNA Triplex Formation of Oligonucleotide Analogues Consisting of Linker Groups and Spacer Segments That Have Opposite Sugar-Phosphate Backbone Polarities," <u>Biochemistry</u> 30:11692-11692 (1991)
	*	Okamoto et al., "Selection <i>in vitro</i> ," <u>Proc. R. Soc. London B.</u> 205:435-442 (1979)
	*	Okamoto et al., "Ribonuclease P: Function and Variation," <u>J. Biol. Chem.</u> 265:3587-3590 (1990)

EXAMINER 	DATE CONSIDERED 4/12/06
--	-----------------------------------

EXAMINER: Initial if not in conformance and whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and corrected. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 00-873-I (500.011)	Serial No. 10/715,285
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: Thompson et al.	
(Use several sheets if necessary)		Filing Date: November 17, 2003	Group: 1635

83	*	Angiogenesis," <i>Science</i> 268:567-569 (1995)
	*	Pardridge et al., "Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier <i>in vivo</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 92:5592-5596 (1995)
	*	Perreault et al., "Mixed Deoxyribo- and Ribo-Oligonucleotides with Catalytic Activity," <i>Nature</i> 344:565-567 (1990) (often mistakenly listed as Perrault)
	*	Perrotta and Been, "A pseudoknot-like structure required for efficient self-cleavage of hepatitis delta virus RNA," <i>Nature</i> 350:434-436 (1991)
	*	Perrotta and Been, "Cleavage of Oligoribonucleotides by a Ribozyme Derived from the Hepatitis δ Virus RNA Sequence," <i>Biochemistry</i> 31:16-21 (1992)
	*	Pietron et al., "Kinetic Characterization of Ribonuclease-Resistant 2'-Modified Hammerhead Ribozymes," <i>Science</i> 253:314-317 (1991)
	*	Pink and Jordan, "Models of Estrogen Receptor Regulation by Estrogens and Antiestrogens in Breast Cancer Cell Lines," <i>Cancer Research</i> 56:2321-2330 (1996)
	*	Plaver and Torrence, "The 2-5A System: Modulation of Viral and Cellular Processes Through Acceleration of RNA Degradation," <i>Pharmacol Ther.</i> 77:55-113 (1998)
	*	Potter et al., "Epithelial-mesenchymal transformation of embryonic cardiac endothelial cells is inhibited by a modified antisense oligodeoxynucleotide to transforming growth factor β 3," <i>Proc. Natl. Acad. Sci. USA</i> 88:1516-1520 (1991)
	*	Prasad et al., "Triple helix formation and the antigen for sequence-specific control of gene expression," <i>Biochimica et Biophysica Acta</i> 1489:181-206 (1999)
	*	Rajulu et al., "A circular trans-acting hepatitis delta virus ribozyme," <i>Nucleic Acids Research</i> 21:453-4258 (1993)
	*	Reich et al., "Building a Kinetic Framework for Group II Intron Ribozyme Activity: Quantitation of Ribozyme Binding and Reaction Rate," <i>Biochemistry</i> 33:2716-2725 (1994)
	*	Reich and Schepartz, "Tethered Oligonucleotide Probes. A Strategy for the Recognition of Structured RNA," <i>J. Am. Chem. Soc.</i> 113:5109-5111 (1991)
	*	Reich et al., "Purification and Properties of a Specific <i>Escherichia coli</i> Ribonuclease which Cleaves Tyrosine Transfer Ribonucleic Acid Precursor," <i>J. Biol. Chem.</i> 247:5243-5251 (1972)
	*	Reich and Seela, "72. 1(2'-Deoxy- β -D-xylofuranosyl)thymine Building Blocks for Solid-Phase Synthesis and Properties of Oligo(2-Deoxyxynucleotides)," <i>Helvetica Chimica Acta</i> 74:748-760
	*	Reich et al., "Reactions of 2-Acyloxyisobutryl Halides with Nucleosides. II. Reactions of

EXAMINER	DATE CONSIDERED
83	4/12/06

EXAMINER: Initial if citation is not in conformance and

considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 00-873-I (500.011)	Serial No. 10/715,285
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: Thompson et al.	
		Filing Date: November 17, 2003	Group: 46 35

		Adenosine," <i>J. Am. Chem. Soc.</i> 95:4025-4030 (1973)
	*	Ryan et al., "Intramolecular Displacement by Neighboring O-Thionobenzoate. Synthesis of 3'-Thioadenosine," <i>J. Org. Chem.</i> 33:1783-1789 (1968)
	*	Santagati et al., "Oligonucleotide Squelching Reveals the Mechanism of Estrogen Receptor Autologous Down-Regulation," <i>Molecular Endocrinology</i> 11:938-949 (1997)
	*	Santoro and Joyce, "A general purpose RNA-cleaving DNA enzyme," <i>Proc. Natl. Acad. Sci. USA</i> 94:4262-4266 (1997)
	*	Santoro et al., "RNA Cleavage by a DNA Enzyme with Extended Chemical Functionality," <i>J. Am. Chem. Soc.</i> 122:2433-2439 (2000)
	*	Sanger et al., "Ribozymes as Potential Anti-HIV-1 Therapeutic Agents" <i>Science</i> 247:1222-1225 (1990)
	*	Scannon et al., "Ribozyme-Mediated Cleavage of c-fos mRNA Reduces Gene Expression of DNA Synthesis Enzymes and Metallothionein," <i>Proc. Natl. Acad. Sci. USA</i> 88:10591-10595 (1991)
	*	Scaevage et al., "Chemical synthesis of biologically active oligoribonucleotides using β -cyanoethyl protected ribonucleoside phosphoramidites," <i>Nucl Acids Res.</i> 18:5433-5441 (1990)
	*	Schnajuk et al., "Antisense Oligonucleotides with Different Backbones," <i>The Journal of Biological Chemistry</i> 274:21783-21789 (1999)
	*	Shibata et al., "Base and sugar requirements for RNA cleavage of essential nucleoside residues in internal loop B of the hairpin ribozyme: implications for secondary structure," <i>Nucleic Acids Research</i> 24:5033-5041 (1996)
	15.	Schneider et al., "Diffusion Enhancement of Drugs by Loaded Nanoparticles in Vitro," <i>Prog. Neuropharmacol. & Biol. Psychiat.</i> 23:941-949 (1999)
	*	Shen et al., "The crystal structure of an AII-RNA hammerhead ribozyme: A proposed mechanism for catalytic cleavage," <i>Cell</i> 81:991-1002 (1995)
	*	Shen et al., "Oligodeoxyribonucleotides containing 1,3-propanediol as nucleoside substitute," <i>Nucleic Acids Research</i> 15:3113-3129 (1987)
	*	Shen et al., "122. Xylose-DNA Containing the Four Natural Bases," <i>Helvetica Chimica Acta</i> 79:1451-1453 (1996)
	*	Shen et al., "83. 1(2'-Deoxy- β -D-xylofuranosyl)cytosine: Base Pairing of Oligonucleotides with a Chemically Altered Sugar-Phosphate Backbone," <i>Helvetica Chimica Acta</i> 77:883-896 (1994)
	*	Shen et al., "Chemical ligation of DNA: The first non-enzymatic assembly of a biologically active oligonucleotide," <i>Nucleic Acids Research</i> 19:4247-4251 (1991)
	*	Shen et al., "Site-directed cleavage of RNA," <i>Nucleic Acids Research</i> 15:4403-4415 (1987)

EXAMINER 	DATE CONSIDERED 4/12/06
--	-----------------------------------

EXAMINER: Initial if citation is not in conformance and

Indicate, whether or not citation is in conformance with MPEP 609; Draw line through citation if not. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 00-873-I (500.011)	Serial No. 10/715,285
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: Thompson et al.	
		Filing Date: November 17, 2003	Group: 1.6 35

JZ	*	Silverman et al., "Selective RNA Cleavage by Isolated RNase L Activated with 2-5A Antisense Chimeric Oligonucleotides," <i>Methods in Enzymology</i> 313:522-533 (1999)
	*	Sontheimer et al., "Metal ion catalysis during splicing of premessenger RNA," <i>Nature</i> 388:801-805 (1997) (volume no. mistakenly referred to as 308)
	*	Stein and Cheng, "Antisense Oligonucleotides as Therapeutic Agents - Is the Bullet Really Magical?" <i>Science</i> 261:1004-1288 (1993)
	*	Stein et al., "A Specificity Comparison of Four Antisense types: Morpholino, 2'-O-Methyl RNA, DNA, and Phosphorothioate DNA," <i>Antisense N.A. Drug Dev.</i> 7:151 (1997)
	*	Strobel et al., "Exocyclic Amine of the Conserved G-U Pair at the Cleavage Site of the <i>Tetrahymena</i> Ribozyme Contributes to 5'-Splice Site Selection and Transition State Stabilization," <i>Biochemistry</i> 35:1211-1211 (1996)
	*	Strobel et al., "Minor Groove Recognition of the Conserved G-U Pair at the <i>Tetrahymena</i> Ribozyme Cleavage Site," <i>Science</i> 267:675-679 (1995)
	*	Strobel et al., "The 2,6-Diaminopurine Riboside-5-Methylisocytidine Wobble Base Pair: An Energetic Substitution for the Study of G-U Pairs in RNA," <i>Biochemistry</i> 33:13824-13835 (1994)
	*	Unger and Cech, "Ribozyme-mediated repair of defective mRNA by targeted trans-splicing," <i>Nature</i> 371:622-622 (1994)
	*	Unger and Cech, "Tethering Ribozymes to a Retroviral Packaging Signal for Destruction of Viral RNA," <i>Science</i> 262:1566-1569 (1993)
	*	Went et al., "Synthesis of 3'-thioribonucleosides and their incorporation into oligoribonucleotides via phosphoramidite chemistry," <i>RNA</i> 3:1352-1363 (1997)
	*	Went et al., "In Vitro Genes," <i>TIBS</i> 17:89-93 (1993)
	*	Went et al., "Construction of a novel RNA-transcript-trimming plasmid which can be used both <i>in vitro</i> for run-off and (G)-free transcriptions and <i>in vivo</i> as multi-sequences transcription vectors," <i>Nucleic Acids Research</i> 19:5125-5130 (1991)
	*	Went et al., "Examination of the catalytic fitness of the hammerhead ribozyme by <i>in vitro</i> selection," <i>Nucleic Acids Research</i> 25:925-925 (1997)
	*	Went et al., "L-Adenylyl-(3'-5')-L-adenosine and L-Adenylyl-(2'-5')-L-adenosine," <i>Biochemistry</i> 9:14 (1970)
	*	Went et al., "Improved accumulation and activity of ribozymes expressed from a tRNA-based polymerase III promoter," <i>Nucleic Acids Research</i> 23:2259-2268 (1995)
	*	Went et al., "Evaluation of N-ras oncogene anti-sense, sense and nonsense sequence

EXAMINER 	DATE CONSIDERED 4/12/06
--	-----------------------------------

EXAMINER: Initial if citation is not in conformance and

red, whether or not citation is in conformance with MPEP 609; Draw line through citation if red. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 00-873-I (500.011)	Serial No. 10/715,285
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: Thompson et al.	
(Use several sheets if necessary)		Filing Date: November 17, 2003	Group: 1635

83		methylphosphonate oligonucleotide analogues," <u>Anti-Cancer Drug Design</u> 3:117-127 (1988)
	*	Torrence et al., "Targeting RNA for degradation with a (2'-5') oligoadenylate-antisense chimera," <u>Proc. Natl. Acad. Sci. USA</u> 90:1300-1304 (1993)
	*	Turner et al., "Improved Parameters for Prediction of RNA Structure," <u>Cold Spring Harbor Symposia on Quantitative Biology Volume LII</u> , pp. 123-133 (1987)
	*	Turner et al., "Free Energy Increments for Hydrogen Bonds in Nucleic Acid Base Pairs," <u>J. Am. Chem. Soc.</u> 109:3783-3785 (1987)
	*	Tyler et al., "Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression," <u>Proc. Natl. Acad. Sci. USA</u> 96:7053-7058 (1999)
	*	Tyler et al., "Specific gene blockade shows that peptide nucleic acids readily enter neuronal cells in vivo," <u>FEBS Letters</u> 421:280-284 (1998)
	*	Uhlenbeck, "A Small Catalytic Oligoribonucleotide," <u>Nature</u> 328:596-600 (1987) (this is listed as Nature 327 in the various specifications, but it is actually 328)
	*	Uhlmann and Peyman, "Antisense Oligonucleotides: A New Therapeutic Principle," <u>Chemical Reviews</u> 90:544-584 (1990)
	*	Usman and Cedergren, "Exploiting the chemical synthesis of RNA," <u>TIBS</u> 17:334-339 (1992)
	*	Usman and McSwiggen, "Ch. 30 - Catalytic RNA (Ribozymes) as Drugs," <u>Annual Reports in Medicinal Chemistry</u> 30:285-294 (1995)
	*	Wassenaar et al., "Automated Chemical Synthesis of Long Oligoribonucleotides Using 2'-O-Silylated Ribonucleoside 3'-O-Phosphoramidites on a Controlled-Pore Glass Support: Synthesis of a 43-Nucleotide Sequence Similar to the 3'-Half Molecule of an <i>Escherichia coli</i> Formylmethionine tRNA," <u>J. Am. Chem. Soc.</u> 109:7845-7854 (1987)
	*	Wassenaar et al., "Chemical modification of hammerhead ribozymes: activity and nuclease resistance," <u>Nucleic Acids Symposium Series</u> 31:163-164 (1994)
	*	Wassenaar et al., "Hammerhead ribozyme engineering," <u>Current Opinion in Structural Biology</u> 1:527-533 (1991)
	*	Wassenaar et al., WO 95/06731 published March 9, 1995, PCT/US94/09342 filed August 19, 1994 for "Nucleotide Containing Enzymatic Nucleic Acid"
	*	Vaughan et al., "Isolation of Hammerhead Ribozymes with Altered Core Sequences by <i>in Vitro</i> Selection," <u>Biochemistry</u> 36:6495-6501 (1997)
	*	Vaughan et al., "Activation of HIV-Specific Ribozyme Activity by Self-Cleavage," <u>Nucleic Acids Research</u>

EXAMINER	83	DATE CONSIDERED	4/12/06
----------	----	-----------------	---------

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and no action is warranted. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		00-873-I (500.011)	10/715,285
(Use several sheets if necessary)		Applicant: Thompson et al.	
		Filing Date:	Group:
		November 17, 2003	1635


		21:3249-3255 (1993)
	*	Verma and Eckstein, "Modified Oligonucleotides: Synthesis and Strategy for Users," <i>Annu. Rev. Biochem.</i> 67:99-134 (1998)
	*	Vyle et al., "Sequence- and Strand-Specific Cleavage in Oligodeoxyribonucleotides and DNA Containing 3'-Thiothymidine," <i>Biochemistry</i> 31:3012-3018 (1992)
	*	Warashina, et al., "Extremely High and Specific Activity of DNA Enzymes in Cells with a Philadelphia Chromosome," <i>Chemistry & Biology</i> , 6(4):237-250 (1999)
	*	Wierasinghe et al., "Resistance to Human Immunodeficiency Virus Type 1 (HIV-1) Infection in Human CD4 ⁺ Lymphocyte-Derived Cell Lines Conferred by Using Retroviral Vectors Expressing an HIV-1 RNA-Specific Ribozyme," <i>Journal of Virology</i> 65:5531-5534 (1994)
	*	Weinstein et al., "Synthesis and Characterization of an RNA Dinucleotide Containing a 3'-S-Phosphorothiolate Linkage," <i>J. Am. Chem. Soc.</i> 118:10341-10350 (1996)
	*	Winter and Uhlenbeck, "The effect of base mismatches in the substrate recognition helices of hammerhead ribozymes on binding and catalysis," <i>Nucleic Acids Research</i> 23:2092-2096 (1995)
	*	Winkler et al., "Paradoxical production of target protein using antisense RNA expression vectors," <i>Gene</i> 149:21-24 (1994)
	*	Winkler et al., "Synthesis, deprotection, analysis and purification of RNA and ribozymes," <i>Nucleic Acids Research</i> 23(14):2677-2684 (1995)
	*	Winkler et al., "A Practical Method for the Production of RNA and Ribozymes," <i>Methods in Molecular Biology</i> 71:59-69 (1997)
	*	Winkler et al., "Oligonucleotides: Opportunities for Drug Therapy and Research," <i>Biopharm</i> , November 1997
	*	Yu et al., "A Hairpin Ribozyme Inhibits Expression of Diverse Strains of Human Immunodeficiency Virus Type 1," <i>Proc. Natl. Acad. Sci. USA</i> 90:6340-6344 (1993)
	*	Yu et al., "Targeted cleavage of mRNA by human RNase P," <i>Proc. Natl. Acad. Sci. USA</i> 89:8006-8010 (1992)
	16.	Yu et al., "Status of Ribozyme and Antisense-Based Developmental Approaches for Anti-HIV-1 Therapy," <i>Annals of the New York Acad. Sci.</i> 660:95-106 (1992)
	*	Yu et al. and Williamson, "The P9.1-P9.2 peripheral extension helps guide folding of the <i>Tetrahymena</i> ribozyme," <i>Nucleic Acids Research</i> 24:854-858 (1996)
	*	Yu et al., "The <i>Tetrahymena</i> Ribozyme Acts Like an RNA Restriction Endonuclease," <i>Nature</i> 323:823 (1986)

EXAMINER 	DATE CONSIDERED 4/12/06
---------------------	-----------------------------------

EXAMINER: Initial if citation is not in conformance and

indicate, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 00-873-I (500.011)	Serial No. 10/715,285
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: Thompson et al.	
		Filing Date: November 17, 2003	Group: 1635

	*	Zhou et al., "Synthesis of Functional mRNA in Mammalian Cells by Bacteriophage T3 RNA Polymerase," Mol. Cell. Biol. 10:4529-4537 (1990)
	*	Zimmerly et al., "A Group II Intron RNA is a Catalytic Component of a DNA Endonuclease Involved in Intron Mobility," Cell 83:529-538 (1995)

EXAMINER		DATE CONSIDERED	4/12/06
----------	---	-----------------	---------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.